Cytek biosciences, inc. (CTKB) 2025Q4 financial report shows revenue of 62.14M USD, with a YoY growth rate of 8.12%. This figure indicates that Cytek biosciences, inc. (CTKB)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of Cytek biosciences, inc. (CTKB)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.